NCT04948333 2026-03-18Asciminib Treatment Optimization in ≥ 3rd Line CML-CPNovartisPhase 3 Completed199 enrolled 13 charts
NCT03358719 2026-02-27DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaRoswell Park Cancer InstitutePhase 1 Completed8 enrolled 9 charts
NCT02730299 2026-02-25Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDSGamida Cell ltdPhase 3 Completed125 enrolled 18 charts 1 FDA
NCT03600155 2026-02-17Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeM.D. Anderson Cancer CenterPhase 1 Completed29 enrolled